CTIBiotech
CTIBiotech is a French-headquartered CRDMO that builds 3D bioprinted human tissue and cell bioassays as predictive, ethical alternatives to animal testing for pharmaceutical, biotech, cosmetic, and academic clients across more than 30 countries.
- Company typePrivate
- Founded2009
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CTIBiotech does
CTIBiotech is a French-headquartered Contract Research, Development, and Manufacturing Organization (CRDMO) that builds predictive 3D bioprinted human tissue and cell bioassays to replace animal testing in preclinical research. Founded in 2009 in Lyon by Professor Colin McGuckin and Dr. Nico Forraz, the company operates an 800m² ISO 9001:2015-certified laboratory in Meyzieu (Lyon), an authorized human-tissue biobank of over 40,000 (referenced up to 50,000) clinical samples, and a recently launched North American subsidiary (CTIBIOTECH USA) at BioLabs for Advanced Therapeutics in Philadelphia. Its commercial offering is organized into three industry-aligned lines: CTI Skin (3D bioprinted skin models, sebaceous and sweat gland systems, the world's first computer-connected bioprinted skin with sensory nervous system, plus CTIBabySkin® and SEBOKIT), CTI Pharma (CTIONCOTEST™ microtumor platform, ONCOKIT Breast, CTILiverbox, and OrgaEar inner ear organoids for cancer, liver, and hearing-disorder drug screening), and CTI Biosourcing (sale of ethically sourced human cells, tissues, and biospecimens via the Independent Biobank catalog).
The company monetizes across five revenue streams: CRDMO fee-for-service contracts (drug screening, toxicology, bioassay co-creation, GLP toxicology and bioanalytical services), direct sale of turnkey research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®), transactional supply of biospecimens from the biobank, custom 3D tissue model co-development projects, and licensing of proprietary New Approach Methodologies (NAMs) and intellectual property — including $15M of IP assets committed to the U.S. market at launch. Pricing is quote-based and project-specific across all streams. Customer segments span pharmaceutical and biotech R&D, cosmetic and dermatocosmetics, medical device and chemical developers, and academic and hospital research laboratories, served through direct enterprise sales in Lyon and Philadelphia, a global authorized distributor network across more than 30 countries, and online research marketplaces (Scientist.com, Biolabs marketplace, Labscoop). The company maintains 11-50 employees and partners with Bpifrance/France 2030, BioDuro, Sanofi, University of Lyon, SATT AxLR, CILCARE, Centre Léon Bérard, Hospices Civils de Lyon, and Transgene, with Edmond de Rothschild holding an exclusive investor relations mandate.
CTIBiotech firmographics
Firmographics- Name
- CTIBiotech
- Legal name
- CTIBIOTECH USA Inc.
- Website
- https://ctibiotech.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CTIBiotech is a French-headquartered CRDMO that builds 3D bioprinted human tissue and cell bioassays as predictive, ethical alternatives to animal testing for pharmaceutical, biotech, cosmetic, and academic clients across more than 30 countries.
- Ownership category
- akta.pro rank
CTIBiotech industry classification
Industry- Product category
- Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassays
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industry
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
Keywords
Where CTIBiotech is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
CTIBiotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Research, Development, and Manufacturing Organization (CRDMO) services: Fee-for-service contract research, drug screening, toxicology testing, bioassay co-creation, GLP toxicology and bioanalytical services for pharmaceutical, biotech, hospitals, and universities, with bi-laboratory capabilities in Lyon and Philadelphia.
- Sale of turnkey research kits and products: Direct sale of ready-to-use kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®) and turnkey biological kits to research and testing laboratories.
- Sale of human cells, tissues, and biosourced biospecimens: Direct supply of human cells and tissues (blood, serum, single cell types, complex tissue requests) from the authorized biobank to researchers worldwide; samples provided for R&D but not for transplant.
- Custom 3D human tissue model development / co-development projects: Custom bioassay co-creation and tailored 3D tissue model development in collaboration with partners (e.g., cancer, immunology, and disease-specific pathologies); CTIONCOTEST dual-revenue strategy of kit sales plus CRDMO services.
- Licensing of proprietary 3D bioprinted bioassays and intellectual property: Provision of proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets; $15 million of intellectual property assets were brought into the U.S. market at launch.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based, project-specific pricing |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels9 records
CTIBiotech product offering
Product offeringCore offering
CTIBiotech is a Contract Research, Development, and Manufacturing Organization (CRDMO) that produces 3D bioprinted human tissues, organoids, and cell-based bioassays from stem cells and ethically sourced surgical tissues. It sells ready-to-use research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin), supplies human biospecimens from its authorized biobank, and provides contract drug screening, toxicology, and custom tissue model development services to pharmaceutical, biotech, cosmetic, chemical, medical device, hospital, and academic clients across more than 30 countries.
Product overview
CTIBiotech operates as a French Contract Research, Development, and Manufacturing Organization (CRDMO) built around three core industry-aligned product lines—CTI Skin (preclinical skin bioassays and 3D bioprinted skin models for cosmetics, dermatology, and devices), CTI Pharma / CTIPharma™ (cancer and disease research bioassays including CTIONCOTEST™ microtumor platforms, ONCOKIT Breast, and CTILiverbox organoid services), and CTI Biosourcing (an ISO-aligned biobank of more than 50,000 ethically sourced human samples distributed via the Independent Biobank live inventory). These three pillars are complemented by a portfolio of named product kits and models—CTIBabySkin®, SEBOKIT, ONCOKIT Breast, CTILiverbox, the CTIONCOTEST™ microtumor platform, the OrgaEar inner-ear organoid project, and a computer-connected bioprinted skin with sensory nervous system—together with a CRDMO contract-research service for assay development, drug screening, and toxicity testing. As of May 2026 this portfolio is delivered through CTIBIOTECH USA™, a Philadelphia-based North American subsidiary operating from BioLabs for Advanced Therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- CTI Skin: Skin tissues innovation and testing; advanced predictive human cell bioassays for skin, including full ex vivo human skin, sebaceous or sweat glands, and skin immune cells. World's most advanced 3D bioprinted skin models.
- CTI Pharma
- CTI Biosourcing
- CTIBabySkin®
- CTISKIN™
- ONCOKIT Breast
- CTILiverbox
- SEBOKIT
- CTIONCOTEST™
Products and services
- CTI Skin (CTISKIN) 3D bioprinted full ex vivo human skin models, including sebaceous and sweat glands and skin immune cells, used for pharmaceutical, cosmetic, chemical, and medical-device testing. Includes the world's first computer-connected lab-grown bioprinted skin with a sensory nervous system for instantaneous cosmetics and fragrance testing.
- CTI Pharma (CTIPharma) Cancer and human disease research bioassays and 3D tissue models for pharmaceutical, biotech, hospital, and university clients, including bioassay co-creation, drug and device testing, plastics and vaccine testing, and oncology screening systems.
- CTI Biosourcing Full-authorized human tissue and cell biobank with capacity of over 40,000 (referenced as over 50,000) clinical samples, connected to an international hospital network. Supplies single cell types, blood, serum, complex tissues, ready-to-use kits, processed cells, and culture media for R&D use (not for transplant).
- ONCOKIT Breast Patient-derived 3D tumor organoid kit that reproduces key breast tumor features including proliferation, viability, and biomarker expression, enabling reliable preclinical assessment of response to chemotherapies, targeted therapies, and immunotherapies.
- CTILiverbox In vitro liver preclinical platform using cell-line based 3D liver organoids that enable assessment of drug metabolism and hepatotoxicity in physiologically relevant human models, providing reproducible and predictive data for pharmaceutical and biotech partners.
- SEBOKIT Standardized ready-to-use primary human sebocyte kit enabling laboratories to perform functional assays without primary cell isolation and culture challenges; supports dermatology and cosmetic research on sebum production, skin homeostasis, microbiota balance, acne, inflammation, and lipid metabolism.
- CTIBabySkin Ethical skin model developed from umbilical cord tissues, designed for cosmetic, dermatological, and pharmaceutical industries. Mimics the biological characteristics of young, delicate, and sensitive skin, enabling product testing in a human-physiology-respecting environment without animal experimentation.
- CTIONCOTEST 3D bioprinted microtumor platform that produces standardized human microtumors directly from a specific cancer patient's primary tumor cells via an automated, industrial-scale process. Targets breast, colon, and pancreatic cancers; mimics the tumor microenvironment (including hypoxic and necrotic zones) with record-breaking cellular viability of 128 days.
- CTIBIOTECH USA CRDMO Services North American CRDMO operations launched in May 2026 from BioLabs for Advanced Therapeutics in Philadelphia's "Cellicon Valley" hub; delivers proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets.
Quantifiable outcome
- 95% of new cancer drugs currently fail in human clinical trials — CTIBIOTECH aims to address this with predictive 3D bioprinted human-derived assays.
- +4 more outcomes
Companies that use CTIBiotech
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles5 records
CTIBiotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
CTIBiotech partnerships and signals
Strategic signalPartnerships
41 partnerships are on record, tiered flagship, core and minor.
- SelectUSA (U.S. Department of Commerce)flagshipU.S. Federal Government program that hosted the official launch of CTIBIOTECH USA at the SelectUSA Investment Summit in Washington, D.C. on May 4, 2026; provided instrumental support for the U.S. expansion.
- Pennsylvania Department of Community and Economic DevelopmentcoreSenior Managing Director David Briel participated in the CTIBIOTECH USA launch at SelectUSA; supported the company's Pennsylvania expansion.
- Chamber of Commerce of Lyon MétropolecoreFrench regional chamber providing ongoing support to CTIBIOTECH's international expansion and the CTIBIOTECH USA launch.
- Région Auvergne-Rhône-AlpescoreRegional government providing ongoing backing for CTIBIOTECH's international development.
- BioLabs for Advanced TherapeuticsflagshipCTIBIOTECH has partnered with Biolabs for its first laboratory and offices in the USA, hosting CTIBIOTECH USA in the Curtis neighborhood of Philadelphia's 'Cellicon Valley' life sciences hub.
- BioDurocoreStrategic partnership to create an integrated preclinical development platform combining drug discovery through IND submission services. Merges BioDuro's discovery chemistry, biology, DMPK, pharmacology, and manufacturing with CTI Biotechnology's GLP toxicology and bioanalytical services.
- Centre Léon BérardcoreLeading French cancer center; key academic/clinical collaborator on the CTIONCOTEST project for 3D bioprinted cancer models.
- Hospices Civils de Lyon (HCL)coreMajor French academic hospital group; key clinical collaborator on the CTIONCOTEST project.
- TransgenecoreFrench biopharmaceutical company specializing in immunotherapy; industrial collaborator on the CTIONCOTEST project.
- GenXMapminorIndustrial partner in the CTIONCOTEST project ecosystem for personalized cancer care.
- Oncodesign ServicesminorIndustrial partner in the CTIONCOTEST project ecosystem; supports preclinical oncology services.
- SATT AxLRcoreSATT AxLR (Occitanie Méditerranée technology transfer office) selected CTIBIOTECH to develop the OrgaEar project, a strategic collaboration to create world-first 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).
- CILCAREcoreCILCARE (hearing health biotech) partnered with CTIBIOTECH on the OrgaEar project to develop 3D bioprinted inner ear organoids from hiPSC for advanced pharmacological screening in hearing disorders.
- Metron TechnologycoreStrategic cooperation agreement signed at the 2024 OBV International Cosmetics Conference in Shanghai for the launch of CTISkin technologies in China.
- SanoficoreOne of Europe's largest pharmaceutical companies developing advanced medicine solutions; listed as a strategic partner on CTIBIOTECH's partnerships page.
- University of Lyon (Université de Lyon)core129,000 students and 11,000 educators/researchers; one of the leading universities in Europe and a CTIBIOTECH strategic partner.
- LyonBiopolecoreAccelerates innovation in health in the Lyon region; CTIONCOTEST project is labelled by the Lyon biopôle Auvergne-Rhône-Alpes competitiveness cluster and integrates this world-class network.
- EMBALL'ISOminorHigh performance temperature-controlled packaging systems and expert in reuse & reverse logistics; supports CTIBIOTECH's biospecimen distribution.
- Business FranceflagshipNational agency supporting the international development of the French economy; ongoing partner backing CTIBIOTECH's U.S. and global expansion including the SelectUSA launch.
- Auvergne Rhône-Alpes EntreprisescoreRegional agency supporting companies to develop and grow with government support; key partner in CTIBIOTECH's international expansion.
- Business PennsylvaniacoreState agency supporting companies to grow and develop in Pennsylvania; partner in CTIBIOTECH USA's Philadelphia expansion.
- The Chamber of Commerce for Greater PhiladelphiacoreBrings area businesses and civic leaders together to promote growth; acknowledged as supporting CTIBIOTECH USA's launch.
- City of PhiladelphiacoreGovernment administration of Philadelphia; welcomed CTIBIOTECH USA into the local biotechnology ecosystem at the SelectUSA launch.
- Cosmetic ValleyminorPromotes national cooperation in the French cosmetics industries; CTIBIOTECH strategic partner.
- Cosmet'InLyon (CED European Center of Dermocosmetology)minorCooperation between cosmetics and testing companies in Central France; CTIBIOTECH partner.
- Société Française de Cosmétologie (SFC) / IFSCCcoreFrench Society of Cosmetology and the International Federation of Cosmetic Chemists; scientific partners recognizing CTIBIOTECH via Top 10 Poster (IFSCC 2025) and Young Researcher Award.
- University of Plovdiv (Medical University Plovdiv)coreBilingual Bulgarian-English medical school university cooperating with CTIBIOTECH in cancer research; key collaborator on the CTIONCOTEST project.
- Franco-Chinese Institute LyonminorCreates cultural, economic and academic bridges between China and France; CTIBIOTECH strategic partner.
- ONLYLYON & Métropole de LyoncoreHelps companies develop in the Lyon region and internationally together with the metropole mayors and government.
- French Army / École Polytechnique / Institut PasteurminorCTIBIOTECH has worked on a significant innovation project with the French Army, LPP, and the Institut Pasteur in Paris.
- EU-Japan Centre for Industrial CooperationminorIndustrial cooperation between Europe and Japan; CTIBIOTECH partner.
- Franco-British and International Business AssociationminorCooperation and networking partner.
- Ville de Meyzieu / AIRMminorLocal government and municipal business support in Meyzieu, where CTIBIOTECH's main French facility is located.
- DNA AvocatscoreLegal representatives of CTIBIOTECH; David Nataf specializes in French corporate law with focus on science and biotechnologies; Vincent Muller handles litigation and defence; Tim Hughes specializes in UK law and international business.
- Advolis Orfis (Baker Tilly)coreFinance representative of CTIBIOTECH; one of the largest finance, accounting, and human resources groups in France; lead contact Valerie Malnoy.
- G.A.C GroupminorAccelerates innovation and performance of companies and territories for responsible development and sustainable growth; advisor for tax, finance, and growth.
- MakilabminorCosmetics / skin advisor Philippe Msika, experienced professional from the cosmetics, beauty, and personal care sector.
- France CertificationminorProvides training and personalized support for certification implementation; regulatory advisor.
- Twinfish DesignminorDesign and marketing company advising on all aspects of communications in French and English.
- CliniSciencesflagshipMajor European life-science distributor and webinar co-host with CTIBIOTECH (e.g., CTISKIN Ethical Skin Testing Solution webinar April 3, 2025).
- Oriental Beauty Valley (OBV)coreChina cosmetics industry cluster in Fengxian, Shanghai. CTIBIOTECH CEO Dr. Nico Forraz announced launch of CTISkin technologies in China via partnership with Metron Technology and OBV at the 2024 OBV International Cosmetics Conference.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
CTIBiotech competitors and assessment
Company assessmentDirect peers
- Organovo: Pioneer in 3D bioprinting of human tissues for preclinical research and therapeutic applications. Closely comparable to CTIBIOTECH's core bioprinting platform and oncology/tissue-modeling thesis, though focused on different tissue franchises.
- BICO (formerly CELLINK): Global leader in bioprinting technologies, bioinks, and lab automation for life sciences. Competes with CTIBIOTECH across 3D bioprinting hardware, consumables, and tissue engineering services.
- MatTek Life Sciences (EpiDerm): Developer of validated 3D reconstructed human tissue models (EpiDerm, EpiOcular, Melanoma) used for cosmetics, pharmaceutical, and chemical safety testing — a direct competitor to CTIBIOTECH's CTI Skin and CTIBabySkin portfolio.
- Emulate: Provider of organ-on-chip platforms (Liver-Chip, Intestine-Chip) for preclinical drug discovery. Comparable to CTIBIOTECH as an alternative-to-animal-testing platform serving pharma R&D, though differentiated by microfluidic chip architecture.
- InSphero: Swiss 3D in vitro microtissue and organoid specialist serving pharma toxicology and disease modeling. Overlaps directly with CTIBIOTECH's 3D microtumor (CTIONCOTEST) and liver (CTILiverbox) offerings.
- Mimetas: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models in drug screening. Competes with CTIBIOTECH for pharma R&D budget allocated to human-relevant preclinical assays.
- SkinEthic (L'Oréal): L'Oréal-owned pioneer of reconstructed human epidermis (Episkin, SkinEthic) for cosmetic and chemical safety testing. Direct competitor to CTIBIOTECH's CTISKIN line, with the strategic backing of a global cosmetics conglomerate.
Emerging players
- Reprocell (Axol Bioscience parent): Stem-cell and iPSC-derived products and services for drug discovery, including organoids and disease models. Comparable to CTIBIOTECH's iPSC-derived OrgaEar and CTI Biosourcing capabilities, with overlap on Axol Biosciences (also a CTIBIOTECH partner).
Broad incumbents
- Charles River Laboratories: Global CRO/CDMO incumbent offering end-to-end preclinical research services. Represents the scaled incumbent alternative against which CTIBIOTECH competes for pharma R&D outsourcing dollars, especially after the BioDuro partnership.
- Lonza: World-leading CDMO with a cell-and-gene-therapies and biological-products footprint. Represents the broader incumbent benchmark for what CTIBIOTECH's CRDMO offering could scale into, including biological manufacturing and biospecimen supply chains.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CTIBiotech social profiles
Digital presenceCTIBiotech compliance and trust
Trust signalCompliance2 records
CTIBiotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
CTIBiotech leadership team
Management profileNumber of profiles
Profiles7 records
CTIBiotech subsidiaries and ownership
Company hierarchySubsidiaries1 record
CTIBiotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CTIBiotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CTIBiotech
What does CTIBiotech do?
CTIBiotech is a Contract Research, Development, and Manufacturing Organization (CRDMO) that produces 3D bioprinted human tissues, organoids, and cell-based bioassays from stem cells and ethically sourced surgical tissues. It sells ready-to-use research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin), supplies human biospecimens from its authorized biobank, and provides contract drug screening, toxicology, and custom tissue model development services to pharmaceutical, biotech, cosmetic, chemical, medical device, hospital, and academic clients across more than 30 countries.
Is CTIBiotech a public or private company?
CTIBiotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CTIBiotech founded?
CTIBiotech was founded in 2009. It employs 11 to 50 people.
Where is CTIBiotech based?
CTIBiotech is headquartered in Lyon, France, in the Europe region.
How does CTIBiotech make money?
Five revenue lines are on record. Contract Research, Development, and Manufacturing Organization (CRDMO) services are the primary driver. The others are sale of turnkey research kits and products, sale of human cells, tissues, and biosourced biospecimens, custom 3D human tissue model development / co-development projects and licensing of proprietary 3D bioprinted bioassays and intellectual property.
Who are CTIBiotech's main competitors?
Direct peers on record are Organovo, BICO (formerly CELLINK), MatTek Life Sciences (EpiDerm), Emulate, InSphero, Mimetas and SkinEthic (L'Oréal). Reprocell (Axol Bioscience parent) is listed as an emerging player. Broad incumbents are Charles River Laboratories and Lonza.
Does CTIBiotech have an API?
No public API is recorded for CTIBiotech.
What industry is CTIBiotech in?
CTIBiotech's product category is Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassays. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 541714 and its SIC code is 8731.